In situ live cell manipulation on LEAP(TM) to empower purification of stem
cells and their differentiated progeny
SAN DIEGO, Aug. 26 /PRNewswire/ -- Cyntellect, a privately-held biotechnology company, and the Burnham Institute for Medical Research ("Burnham") today announced they have entered into a joint collaboration to develop new applications on Cyntellect's in situ live cell imaging and laser processing product (called LEAP(TM)) to accelerate research by Burnham's scientists. The collaboration efforts will focus on developing applications of LEAP for automated purification of stem cells, stem cell colonies and the differentiated cells derived from stem cells. Cyntellect and Burnham expect these new applications will accelerate discovery of new knowledge of stem cell differentiation factors and pathways, as well as generate cell populations that may be used to deliver the potential therapeutic benefits of stem cells. Under the agreement, Burnham will gain access to LEAP and Cyntellect will gain certain commercial rights to discoveries under the collaboration.
"In situ laser processing with LEAP has provided us the unique ability to purify rare adherent cell types in an efficient, automated and sterile manner," said Mark Mercola, Ph.D., Professor and Associate Director, Del E. Webb Neuroscience, Aging and Stem Cell Research Center. "We also believe LEAP can be a transforming technology in the downstream use of stem cells and their progeny as it has clear potential as a sample preparation system for adherent cell types derived from stem cell populations."
LEAP is an automated live cell analysis and processing system that
combines high-speed optical imaging (brightfield or fluorescence) and
real-time image analysis with high-speed in situ laser manipulation of
cells. Using LEAP, researchers have demonstrated: (i) accelerated
functional cloning of cells, including highly-secreting cells for
|SOURCE Cyntellect, Inc.|
Copyright©2008 PR Newswire.
All rights reserved